Drug
AMG 757 clinical trials
Also written Tarlatamab, AMG 757 and Imdelltra.
Keep track of what changes. Save the AMG 757 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2025 (10); 1 more planned to start later
| Year | Studies |
|---|---|
| 2021 | 3 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 10 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 16
Amgen (12) · AbbVie (1) · Vall d'Hebron Institute of Oncology (1) · PrECOG, LLC. (1) · AIO-Studien-gGmbH (1) · ETOP IBCSG Partners Foundation (1) · National Taiwan University Hospital (1) · Centre Leon Berard (1)
Often tested with
Tested in the same studies.
Atezolizumab (3) · Carboplatin (2) · Zeluvalimab (1) · Turmetabart adizutecan (1) · Etakafusp alfa (1) · Temozolomide (1) · Etoposide (1) · Cisplatin (1)
Studies
Open first, then newest update. How each study uses AMG 757 is read from its arms, and is right about nine times in ten.
Testing it · 30
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung CancerNot yet recruitingPhase 2AbbVieNCT07895056Written as Tarlatamab
- Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance StatusRecruitingPhase 2AIO-Studien-gGmbHNCT07803848Written as Tarlatamab
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)RecruitingPhase 1AmgenNCT07037758Written as Tarlatamab
- A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2RecruitingPhase 2ETOP IBCSG Partners FoundationNCT07203053Written as Tarlatamab
- Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)RecruitingPhase 2National Taiwan University HospitalNCT06816394Written as Tarlatamab
- Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)RecruitingPhase 3AmgenNCT07778316Written as Tarlatamab
- Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System TumorsRecruitingPhase 1/2Centre Leon BerardNCT07243470Written as Tarlatamab
- Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI TreatmentRecruitingPhase 2Sehhoon ParkNCT06830694Written as Atezolizumab, Etoposide, Carboplatin, Tarlatamab
- Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)RecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07016230Written as Tarlatamab
- A Study of Tarlatamab for People With Prostate CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07111507Written as Tarlatamab
- Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)Not yet recruitingPhase 1Vall d'Hebron Institute of OncologyNCT07788677Written as Tarlatamab
- Tarlatamab for SCLC Brain MetastasesRecruitingPhase 2Maastricht University Medical CenterNCT07402343Written as Tarlatamab
- Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC PatientsRecruitingPhase 2Fundación GECPNCT07242547Written as Tarlatamab
- Tarlatamab for the Treatment of Extensive Stage Small-cell Lung CancerRecruitingPhase 2Asrar AlahmadiNCT07423585Written as Tarlatamab
- Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)RecruitingPhase 1AmgenNCT06598306Written as Tarlatamab
- Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung CancerNot yet recruitingPhase 3PrECOG, LLC.NCT07637513Written as Tarlatamab
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingPhase 1GlaxoSmithKlineNCT06551142Written as Tarlatamab
- Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma PatientsRecruitingPhase 2Inkeun ParkNCT06893783Written as Tarlatamab
- Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)RecruitingPhase 3Intergroupe Francophone de Cancerologie ThoraciqueNCT06937905Written as Tarlatamab
- Study of How Safe and Effective Tarlatamab is in Brain CancersRecruitingPhase 2University Health Network, TorontoNCT06776250Written as Tarlatamab
See all 30 studies that test AMG 757 →
Given in every arm · 6 — AMG 757 is usual care beside what is tested
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsRecruitingPhase 1/2University of ArizonaNCT06814496Written as Tarlatamab
- Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)RecruitingPhase 1AmgenNCT07531095Written as Tarlatamab
- Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamabTerminatedPhase 2Grupo Espanol de Tumores NeuroendocrinosNCT07061080Written as Tarlatamab
- First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)Active, not recruitingPhase 1AmgenNCT05361395Written as Tarlatamab
- Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)Active, not recruitingPhase 1AmgenNCT06898957Written as Tarlatamab
- Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)Active, not recruitingPhase 1AmgenNCT03319940Written as Tarlatamab
Codes
What other systems call AMG 757 · ClinicalTrials.gg INT001867
- MeSH (NLM) C000722655AMG 757Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 74X82ST8Q1TARLATAMABConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722655 | AMG 757 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 74X82ST8Q1 | TARLATAMAB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.